PacBio Completes Sale of Short-Read Sequencing Assets

GlobeNewswire

MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio , a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select intellectual property and other assets related to PacBio’s short-read DNA sequencing technology and related clustering, sequencing reagent, and detection technologies to Illumina, Inc.

PacBio received $48.1 million in net cash proceeds from the transaction. Under the terms of the agreement, Illumina assumed certain liabilities and granted a non-exclusive license certain intellectual property back to PacBio.

“Last year, in response to challenging macroeconomic conditions, we made the strategic decision to pause development of our high-throughput short-read sequencing platform so that we can take full advantage of our innovations in the long-read sequencing market,” said Christian Henry, President and Chief Executive Officer. “This transaction further sharpens our focus and meaningfully strengthens our balance sheet. It positions us to drive adoption of our differentiated long-read sequencing platform and execute on the next phase of growth. For example, we have accelerated development of SPRQ-Nx chemistry to launch globally. SPRQ-Nx offers the most complete view of the genome at a competitive pricing structure.”

The transaction closed on January 30, 2026.

About PacBio

PacBio is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including, but not limited to, statements relating to PacBio’s current expectations, estimates and assumptions about the asset sale and the potential benefits thereof, including driving the adoption of PacBio’s differentiating long-read sequencing platform; and PacBio’s growth plans and initiatives as well as the expected financial impact and timing of these plans and initiatives. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, but not limited to, failure to realize the anticipated benefits of the asset sale; unforeseen liabilities; challenges inherent in developing, manufacturing, launching, marketing and selling new products, and achieving anticipated new sales; potential cancellation of existing instrument orders; assumptions, risks and uncertainties related to the ability to attract new customers and retain and grow sales from existing customers; risks related to PacBio’s ability to successfully execute and realize the benefits of dispositions or acquisitions; the impact of new, increased or enhanced tariffs and export restrictions; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; potential product performance and quality issues and potential delays in development timelines; the possible loss of key employees, customers, or suppliers; customers and prospective customers curtailing or suspending activities using PacBio’s products; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio’s patents or proprietary rights; risks associated with international operations; and other risks associated with general macroeconomic conditions and geopolitical instability. Additional factors that could materially affect actual results can be found in PacBio’s most recent filings with the Securities and Exchange Commission, including PacBio’s most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.

Contacts

Investors:

ir@pacb.com

Media:

pr@pacb.com

Risk Warnings and Disclaimers

You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.

Add to Favorites

Standard BioTools Completes Sale of SomaLogic to Illumina

GlobeNewswire

Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments

Approximately $550 Million in cash & cash equivalents on balance sheet at close, excluding potential future earnouts, to fuel inorganic growth strategy

Continuing Operations on track to achieve positive adjusted EBITDA in 2026

BOSTON, Mass., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (the “Company” or “Standard BioTools”) today announced it has completed the previously announced sale of SomaLogic to Illumina, Inc. (“Illumina”) for $350 million in upfront cash and up to $75 million in near-term earnout payments for aggregate cash consideration of up to $425 million plus specified royalties.

“The closing of this transaction marks a major milestone in our strategic transformation. We are lean, focused and extremely well positioned, and emerge today far stronger than we were yesterday,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “We are now financially resourced to pursue disciplined M&A that accelerates growth and scale like few similarly sized peers in our industry can.”

Transaction Details

With the sale of SomaLogic to Illumina, which includes SomaScan® Assay Services, Authorized Sites and KREX™, Standard BioTools received an upfront payment of $350 million, subject to customary adjustments, and is eligible to receive up to $75 million in earnout payments, consisting of up to $25 million based on 2025 performance and up to $50 million based on 2026 performance, payable upon the achievement of specified targets for net revenue generated from SOMAmer-based assay services and related products.1

Standard BioTools will also receive a 2% royalty on net revenues generated from sales of SOMAmer-based NGS library preparation kits for 10 years and a co-exclusive license to the intellectual property relating to Single SOMAmer commercialization in singleplex affinity assays.

Following the closing of the transaction, as of January 30, 2026, Standard BioTools estimates a cash and cash equivalents balance of approximately $550 million. This approximate cash and cash equivalents balance is unaudited and may be adjusted as a result of, among other things, completion of financial closing procedures and internal reviews. This financial information does not represent a comprehensive statement of the Company’s current financial results.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding future financial and business performance, including with respect to potential earnout payments and royalty streams; expected cash and cash equivalents; operational and strategic plans; deployment of capital; market and growth opportunity and potential; and the potential to realize the expected benefits of the transaction. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning.

Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to: risks of stockholder litigation relating to the transaction, including resulting expense the potential that the expected benefits and opportunities of the transaction may not be realized or may take longer to realize than expected; risks that the anticipated benefits and synergies of prior and potential future acquisitions and the integration of any such businesses, including the potential for such transactions to drive long-term profitable growth, may not be fully realized or may take longer to realize than expected; risks that the Company may not realize expected cost savings from such transactions; possible integration, restructuring and transition-related disruption resulting from such transactions, including through the loss of customers, suppliers, and employees and adverse impacts on the Company’s development activities and results of operation; integration and restructuring activities, including customer and employee relations, management distraction, and reduced operating performance; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company’s plans, or both; risks that the Company’s expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company’s business or external market conditions; anticipated NIH funding pressures; the expected effect from U.S. export controls and the expected impact from tariffs; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company’s products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company’s research and development activities and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition.

For information regarding other related risks, see the “Risk Factors” section in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 11, 2025, in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the SEC on August 15, 2025 and in the Company’s other filings with the SEC.

These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.

About Standard BioTools Inc.

Standard BioTools Inc. , has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop better medicines faster. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.

Patent and License Information: standardbio.com/legal/notices.

Investor Contact:

ir@standardbio.com

1 The earnout payment of up to $25 million based on 2025 performance will be determined in accordance with the terms of the definitive transaction documentation, including customary review procedures between Standard BioTools and Illumina.

Risk Warnings and Disclaimers

Add to Favorites

Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products

Modular Finance

Illumina

-0.92%

Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA sequencing and array-based technologies, to provide Illumina sequencing instruments and related products to Devyser customers.

Under the agreement, Devyser will be able to offer selected Illumina sequencing instruments together with Devyser’s reagent solutions, enabling customers to access advanced sequencing technology with reduced upfront capital investment. The framework is designed to simplify procurement, accelerate implementation, and support laboratories in expanding their testing capabilities.

“This agreement strengthens our ability to deliver complete, scalable solutions to our customers,” said Theis Kipling, Chief Commercial Officer at Devyser. “By combining Illumina’s industry-leading sequencing platforms with Devyser’s validated genetic testing assays, we can lower barriers to adoption and help laboratories more quickly implement high-quality genetic testing.”

The model allows Devyser customers to access sequencing instruments through an ongoing reagent commitment rather than a traditional purchase model. This approach is particularly attractive for clinical laboratories seeking predictable costs, faster onboarding, and flexibility as testing volumes grow.

Illumina’s sequencing platforms are widely used in clinical and research settings worldwide. The agreement complements Devyser’s strategy to provide end-to-end testing solutions that support laboratories across clinical genetics and transplant diagnostics.

“This agreement underscores Illumina’s focus on making next-generation sequencing more accessible and easier to implement,” said Bas Verhoef, SVP and Head of Region, EMEA & Latin America, Illumina. “Partnering with Devyser will simplify workflows and support customers in delivering high-quality, scalable solutions for testing.”

For more information, please contact:

Jan Wahlström, CEO

E-mail:ir@devyser.com

Telephone: +46 8 562 158 50

Theis Kipling, CCO

E-mail:ir@devyser.com

Telephone: +46 8 562 158 50

About Devyser

Devyser is redefining how laboratories approach genetic testing. As your true one-stop shop, we offer streamlined solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency.

Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes.

We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta and maintain sales offices across Europe and the US.

Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio.

Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company´s Certified Adviser is Redeye AB.

Discover how we're shaping the future of lab diagnostics atwww.devyser.com.

Attachments

Devyser enters Strategic Supply Agreement with Illumina to offer sequencing instruments and products

Risk Warnings and Disclaimers

Add to Favorites

Life Sciences Tools & Services Stocks Q3 Teardown: Illumina (NASDAQ:ILMN) Vs The Rest

Stock Story

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Illumina and its peers.

The life sciences tools and services sector supports biotech and pharmaceutical R&D and commercialization by providing lab equipment, data analytics, and clinical trial services. These companies benefit from recurring revenue and high margins on specialized products. Looking ahead, the sector is supported by tailwinds like advancements in genomics, personalized medicine, and the use of AI in drug discovery. However, the persistent challenge is dependence on the R&D budgets of large pharmaceutical companies and the volatility of smaller biotech firms. Future headwinds include uncertain research funding and pricing pressures from cost-conscious customers.

The 21 life sciences tools & services stocks we track reported a strong Q3. As a group, revenues beat analysts’ consensus estimates by 1.7% while next quarter’s revenue guidance was 1.4% below.

Luckily, life sciences tools & services stocks have performed well with share prices up 21.3% on average since the latest earnings results.

Illumina

Pioneering the ability to read the human genome at unprecedented speed and affordability, Illumina develops and sells advanced DNA sequencing and microarray technologies that allow researchers and clinicians to analyze genetic variations and functions.

Illumina reported revenues of $1.08 billion, flat year on year. This print exceeded analysts’ expectations by 1.8%. Overall, it was an exceptional quarter for the company with an impressive beat of analysts’ full-year EPS guidance estimates and a beat of analysts’ EPS estimates.

"I am pleased to announce that the Illumina team delivered Q325 results that exceeded the high-end of our guidance range for revenue and earnings, driven by revenue acceleration in clinical, our largest market segment," said Jacob Thaysen, Chief Executive Officer.

Interestingly, the stock is up 54.1% since reporting and currently trades at $152.60.

Best Q3: 10x Genomics

Founded in 2012 by scientists seeking to overcome limitations in traditional biological research methods, 10x Genomics develops instruments, consumables, and software that enable researchers to analyze biological systems at single-cell resolution and spatial context.

10x Genomics reported revenues of $149 million, down 1.7% year on year, outperforming analysts’ expectations by 4.6%. The business had an incredible quarter with a beat of analysts’ EPS estimates and revenue guidance for next quarter exceeding analysts’ expectations.

The market seems happy with the results as the stock is up 74.4% since reporting. It currently trades at $22.68.

Weakest Q3: Avantor

With roots dating back to 1904 and embedded in virtually every stage of scientific research and production, Avantor provides mission-critical products, materials, and services to customers in biopharma, healthcare, education, and advanced technology industries.

Avantor reported revenues of $1.62 billion, down 5.3% year on year, falling short of analysts’ expectations by 1.4%. It was a softer quarter as it posted a slight miss of analysts’ revenue estimates.

Avantor delivered the slowest revenue growth in the group. As expected, the stock is down 18.9% since the results and currently trades at $12.23.

Read our full analysis of Avantor’s results here.

Revvity

Formerly known as PerkinElmer until its rebranding in 2023, Revvity provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure.

Revvity reported revenues of $698.9 million, up 2.2% year on year. This print was in line with analysts’ expectations. Taking a step back, it was a satisfactory quarter as it also recorded a decent beat of analysts’ full-year EPS guidance estimates but organic revenue in line with analysts’ estimates.

Revvity scored the highest full-year guidance raise among its peers. The stock is up 17.8% since reporting and currently trades at $116.53.

Read our full, actionable report on Revvity here, it’s free.

Waters Corporation

Founded in 1958 and pioneering innovations in laboratory analysis for over six decades, Waters develops and manufactures analytical instruments, software, and consumables for liquid chromatography, mass spectrometry, and thermal analysis used in scientific research and quality testing.

Waters Corporation reported revenues of $799.9 million, up 8% year on year. This number surpassed analysts’ expectations by 2.4%. More broadly, it was a satisfactory quarter as it also logged a solid beat of analysts’ organic revenue estimates but a miss of analysts’ EPS guidance for next quarter estimates.

The stock is up 14.8% since reporting and currently trades at $396.71.

Read our full, actionable report on Waters Corporation here, it’s free.

Risk Warnings and Disclaimers

Add to Favorites

PacBio (PACB) Stock Is Up, What You Need To Know

Stock Story

Pacific Biosciences of California

-4.41%

What Happened?

Shares of genomics company Pacific Biosciences of California jumped 2.9% in the morning session after news from a previous session revealed that Cathie Wood's investment firm, ARK Invest, had purchased a substantial number of its shares. The stock's upward trend began in a prior session when it gained 6.1% following the news of the significant purchase by the well-known investment firm. The continued buying interest suggested that investors remained optimistic about the company's prospects following the high-profile investment, which is often seen as a vote of confidence in a company's technology and future growth.

After the initial pop the shares cooled down to $1.89, up 0.9% from previous close.

What Is The Market Telling Us

PacBio’s shares are extremely volatile and have had 84 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 2 days ago when the stock gained 6.1% on the news that Cathie Wood's investment firm, ARK Invest, purchased a substantial number of its shares. The firm's transaction reports showed the acquisition of 423,426 shares of Pacific Biosciences of California for approximately $724,058. This move was part of a series of end-of-year portfolio adjustments by ARK Invest. The purchases indicated a strategic tilt toward the biotechnology sector as the firm increased its holdings in several biotech companies.

Investors who bought $1,000 worth of PacBio’s shares 5 years ago would now be looking at an investment worth $71.51.

Risk Warnings and Disclaimers

Add to Favorites

Stocks making big moves this week: PacBio, Crocs, FuelCell Energy, AMC Entertainment, and ON24

Stock Story

Pacific Biosciences of California

Check out the companies making headlines this week:

PacBio : Genomics company Pacific Biosciences of California rose by 6.1% on Wednesday after Cathie Wood's investment firm, ARK Invest, purchased a substantial number of its shares. See our full article here.

Crocs : Footwear company Crocs fell by 3% on Monday after the stock tested a technical resistance level amid underlying investor concerns about slowing growth. See our full article here.

FuelCell Energy : Carbonate fuel cell technology developer FuelCell Energy fell by 9.8% on Wednesday after the company filed for a common stock offering of up to $200 million See our full article here.

AMC Entertainment : Theater company AMC Entertainment fell by 3.2% on Monday after investor concerns about the company's underlying financial health overshadowed a report of strong moviegoer attendance over the final weekend of 2025. See our full article here.

ON24 : Digital engagement platform ON24 rose by 36.9% on Tuesday after the company agreed to be acquired by Cvent in an all-cash transaction. See our full article here.

Risk Warnings and Disclaimers

Add to Favorites

Stocks making big moves yesterday: FuelCell Energy, Corcept, and PacBio

Stock Story

Pacific Biosciences of California

-4.41%

Check out the companies making headlines yesterday:

Corcept : Biopharma company Corcept Therapeutics fell by 51.4% on Wednesday after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) rejecting the company's New Drug Application for relacorilant. See our full article here.

Risk Warnings and Disclaimers

Add to Favorites